Immy, a molecular diagnostic company, recently acquired OLM Diagnostics, based in the United Kingdom.
“This strategic move not only expands our product portfolio for our customers, but also strengthens our commitment to empowering laboratorians and clinicians with cutting-edge tools for precise identification of fungal disease. Together, we embark on a journey fueled by innovation and collaboration, poised to redefine the standards of fungal diagnostics and pave the way for better healthcare outcomes worldwide," said Sean Bauman, the CEO of IMMY.
The company expects to capitalize on OLM's robust portfolio and IMMY's legacy of excellence to provide innovative solutions that blend tradition with modernity, the company said in a statement. The goal is to provide superior quality, foster innovation and make a positive impact in healthcare.
“In our 10-year journey, OLM's focus on diagnostic innovation for fungal infections, fueled by collaboration and a strong team ethic, has set us apart. Joining IMMY marks an exciting new chapter. We are thrilled to leverage IMMY’s additional resources and capabilities to enhance our product portfolio and expand our molecular diagnostics range in this field. This merger creates a comprehensive portfolio, empowering us to better serve patients in this often overlooked area,” said Ged McGonnell, OLM’s managing director and founder.
From Immy press materials.
